South Korean Government Simplifies Biosimilar Approval Process to Accelerate New Drug Development
The South Korean government has recently decided to simplify the product approval process for biosimilars (generic versions of biopharmaceuticals). This measure reflects the government's commitment to fostering the bio-health industry as a future growth engine for the nation.
The core of this deregulation is the exemption of Phase 3 clinical trial results, which were previously mandatory in the biosimilar approval process, provided that certain conditions are met. Until now, clinical trials have been a significant burden on companies due to the substantial time and costs involved.
Through this measure, the government aims to create an environment where domestic pharmaceutical companies can focus more on the development of new drugs and biosimilars. In particular, it is expected that a shortened development period will allow patients to access affordable and effective medicines more quickly.
The in-vitro diagnostics industry and the bio-health sector play a crucial role in responding to infectious diseases, precision medicine, and the management of chronic diseases. Attention is now focused on whether this regulatory innovation will serve as an opportunity to strengthen the competitiveness of the Korean pharmaceutical industry and expand its presence in the global market.